[The National Comprehensive Cancer Network (NCCN) recently made news when it named the genomic/somatic test Decipher Prostate Genomic Classifier as the first test of its kind to be recognized as having high-level evidence of benefit.
Howard. Thanks for another fantastic article. I do have to admit that a lot of it is well over my head but it appears that Decipher is nt the best test for biopsy tissue. Of all the specialists I have talked too (5 total) not one suggested this. other than Randy Vincent who told me that I was not the intended target ( low volume Gleason 6) for his Decipher study. Stay well, Jamie
I am not sure that Dr. Toward accurately represented the effectiveness of using Oncotype DX as a predictive test for death at ten years and metastasis in ten years. My Oncotype DX test results provided a predictive score for both. I have used that scoring as a key element in decision making to remain on AS
Richard, I work for the company that currently markets OncotypeDx GPS (MDxHealth) and prior to that, the company that developed GPS (Genomic Health). The language can get a bit confusing. When you say a test is "predictive" it means it's predictive for a particular therapeutic benefit. For example, Genomic Health developed the OncotypeDx Recurrence Score for women with breast cancer to predict chemotherapy benefit. ArteraAI is predictive for ADT benefit in high risk patients. It's actually the only test in the space that can currently claim that. OncotypeDx GPS, Prolaris and Decipher are actually "prognostic" in the information they provide in the biopsy setting. Each test has different endpoints, prognosticating liklihood of adverse pathology (GPS and Decipher though different definitions of adverse pathology) and death and metastasis (GPS, Prolaris and Decipher). It's also important to note the raw score which represents the genomic expression. In the case of GPS this is a score from 0-100. Each test has it's strength depending on what question you are asking such as active surveillance versus definitive treatment or radiation after RP, etc.
If you have an expert who can explain OncotypeDX GPS vs. the competition, I'd be happy to run an article. There is a lot of confusion about these tests.
Thanks, Jamie.
It is confusing. The docs can disagree.
Howard
Howard. Thanks for another fantastic article. I do have to admit that a lot of it is well over my head but it appears that Decipher is nt the best test for biopsy tissue. Of all the specialists I have talked too (5 total) not one suggested this. other than Randy Vincent who told me that I was not the intended target ( low volume Gleason 6) for his Decipher study. Stay well, Jamie
Thanks, Richard.
I'll ask Dr. Tward.
Howard
I am not sure that Dr. Toward accurately represented the effectiveness of using Oncotype DX as a predictive test for death at ten years and metastasis in ten years. My Oncotype DX test results provided a predictive score for both. I have used that scoring as a key element in decision making to remain on AS
Richard M.
Richard, I work for the company that currently markets OncotypeDx GPS (MDxHealth) and prior to that, the company that developed GPS (Genomic Health). The language can get a bit confusing. When you say a test is "predictive" it means it's predictive for a particular therapeutic benefit. For example, Genomic Health developed the OncotypeDx Recurrence Score for women with breast cancer to predict chemotherapy benefit. ArteraAI is predictive for ADT benefit in high risk patients. It's actually the only test in the space that can currently claim that. OncotypeDx GPS, Prolaris and Decipher are actually "prognostic" in the information they provide in the biopsy setting. Each test has different endpoints, prognosticating liklihood of adverse pathology (GPS and Decipher though different definitions of adverse pathology) and death and metastasis (GPS, Prolaris and Decipher). It's also important to note the raw score which represents the genomic expression. In the case of GPS this is a score from 0-100. Each test has it's strength depending on what question you are asking such as active surveillance versus definitive treatment or radiation after RP, etc.
Sabrina,
Thanks for the note.
If you have an expert who can explain OncotypeDX GPS vs. the competition, I'd be happy to run an article. There is a lot of confusion about these tests.
How about some light?
Howard
Howard, I’ll pass along your suggestion to our executive team so they can make a suggestion.